by 
The acute bacterial skin and skin structure infections (ABSSSI) market consists of antibiotics administered intravenously or orally to treat complicated and uncomplicated skin infections caused by susceptible gram-positive bacterial pathogens. Some of the commonly used antibiotics include beta-lactams, glycopeptides, oxazolidinones. The antibiotics rapidly resolve the signs and symptoms of infection, prevent spread to deeper tissues and structures, and reduce the need for surgical intervention or hospitalization.
The global Acute Bacterial Skin and Skin Structure Infections market is estimated to be valued at US$ 3,466.6 Mn in 2024 and is expected to exhibit a CAGR of 6.0% over the forecast period 2023 to 2030.
Key Takeaways
Key players operating in the ABSSSI market are Fresenius SE & Co. KGaA, Pfizer, Inc., Amneal Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Sandoz Inc., Aurobindo Pharma Ltd., AbbVie, Inc., Melinta Therapeutics, Inc., Accord Healthcare Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Paratek Pharmaceuticals, Inc. The growing prevalence of skin infections and increasing awareness about available treatment options is expected to drive the market growth during the forecast period. Moreover, major market players are focusing on geographic expansion and new product launches to consolidate their market position.
The increasing incidence of diabetes, obesity, and nosocomial infections are some of the key factors responsible for rising antibiotic resistant bacterial skin infections globally. Furthermore, lifestyle changes and increasing outdoor recreational activities have also contributed to the disease burden. The growing geriatric population who are more vulnerable to such infections also present significant growth opportunities for ABSSSI drugs.
Market Key Trends
One of the key trends witnessed in the ABSSSI market is the rising focus on developing novel anti-infective drugs to overcome antibiotic resistance. Several companies are conducting clinical trials to evaluate new drug candidates with alternative mechanisms of action, such as combination therapies and drugs targeting virulence factors and biofilm formation. Furthermore, there is a growing emphasis on developing rapid point-of-care diagnostic tests to enable early and accurate detection of causative pathogens, guide optimal treatment decisions, and curb unnecessary antibiotic use. This will go a long way in managing the current resistance challenge.
Porter’s Analysis
Threat of new entrants: Low, due to high costs of R&D, clinical trials, regulatory approvals and established brands.
Bargaining power of buyers: Moderate, as standard treatment options are available.
Bargaining power of suppliers: Moderate, as suppliers can influence prices due to patent protection of drugs.
Threat of new substitutes: Low, as acute skin infections have limited treatment alternatives.
Competitive rivalry: High, as the market has major global players continuously competing on brand recognition, quality and pricing.
Geographical Regions
North America region accounts for the largest share in acute bacterial skin and skin structure infections market in terms of value, owing to high per capita healthcare expenditure and growth in cases of SSIs. The United States represents the major market for ABSSSI drugs in the region.
Asia Pacific region is expected to witness the fastest growth during the forecast period owing to rising healthcare infrastructure, increasing awareness regarding skin infections and growth in generic drug market in emerging countries like India and China. Improvements in healthcare facilities and rise in disposable incomes have propelled the growth of the market in the region.
Geographical Regions
The European region dominates the global acute bacterial skin and skin structure infections market in terms of value. It has a well-established healthcare system and major drug manufacturers are located in the region. Germany leads the ABSSSI market in Europe. Rising incidence of post-surgery SSIs and growing antibiotic resistance supports market growth.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
